Advancements in intrauterine treatment of fetal sacrococcygeal teratoma
10.3760/cma.j.cn131148-20240716-00386
- VernacularTitle:胎儿骶尾部畸胎瘤宫内治疗进展
- Author:
Qingguo ZOU
1
;
Shanshan LIU
;
Danping LU
;
Hongyun ZHANG
;
Jiang ZHU
Author Information
1. 湖州市中心医院 浙江大学医学院附属湖州医院超声科，湖州 313000
- Publication Type:Journal Article
- Keywords:
Ultrasonography;
Fetal sacrococcygeal teratoma;
Intrauterine treatment;
Radiofrequency ablation;
Laser ablation
- From:
Chinese Journal of Ultrasonography
2025;34(1):85-89
- CountryChina
- Language:Chinese
-
Abstract:
Fetal sacrococcygeal teratoma（SCT）is a rare condition，but the prognosis of fetuses diagnosed with SCT prenatally is generally poor，with a mortality rate of 13% to 50%. The primary causes of death include fetal hydrops and high?output heart failure，while other causes include tumor rupture，hemorrhage，preterm labor，dystocia，or malignant teratoma invasion of surrounding tissues. For large tumors，especially those with rich blood supply or rapid growth，intrauterine treatment should be considered to prevent arteriovenous shunting，reduce tumor size，and reverse fetal heart failure and hydrops. This approach aims to allow the fetus to grow safely to a viable gestational age，after which the tumor can be completely removed by secondary surgery following cesarean delivery or natural childbirth. Currently，there are five main intrauterine treatment strategies：①Ultrasound?guided cystic teratoma aspiration：single or multiple aspirations，intrauterine continuous drainage，or prenatal aspiration；②Ultrasound?guided alcohol sclerotherapy；③Open fetal surgery；④Laser ablation：fetoscopic?guided ablation of feeding vessels of the teratoma，or ultrasound?guided laser ablation；⑤ Ultrasound?guided radiofrequency ablation（RFA）.According to the literature，the latter two minimally invasive intrauterine treatment methods show better outcomes for teratomas containing solid components and are gradually becoming the mainstream treatment options.
